BioArctic AB (publ) (0RV2.L)
| Previous close | 89.65 |
| Open | 95.00 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 94.15 - 96.90 |
| 52-week range | 94.15 - 391.00 |
| Volume | |
| Avg. volume | 13,915 |
| Market cap | N/A |
| Beta (5Y monthly) | -0.15 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Leqembi® (lecanemab) launched in China
BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today announced today that Leqembi® (brand name in China: "乐意保®", generic name: lecanemab) has been launched in China. Leqembi received approval in January 2024 as a treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia. China is the third country to launch Leqembi following the United States and Japan.
- PR Newswire
FDA accepts filing of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's Disease
BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supplemental Biologics License Application (sBLA) for less frequent monthly lecanemab-irmb (U.S. brand name: Leqembi) intravenous (IV) maintenance dosing. A Prescription Drug User Fee Act (PDUFA) action date is set for January 25, 2025. In the US, Leqembi is indicated for the treatment of Alzheimer's disease (AD) in patients with mild cognitive
- PR Newswire
BioArctic and Eisai sign research evaluation agreement regarding BAN2802
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic AB and Eisai Co., Ltd., have entered into a research evaluation agreement regarding BAN2802, a potential new treatment combining BioArctic's proprietary BrainTransporter™ technology with an undisclosed Alzheimer drug candidate. At the end of the collaboration, Eisai will evaluate the data generated and decide if they chose to exercise an option to license BAN2802 for the treatment of Alzheimer's disease.
